BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38506033)

  • 1. Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Ji W; Jiang Y; Li Y; Mao W; Teng L
    Neoplasma; 2024 Feb; 71(1):88-97. PubMed ID: 38506033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
    Wang H; Han Y
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
    Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
    Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organ preservation strategies after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a multicenter retrospective cohort study.
    Hui B; Wang X; Wang X; Qiao B; Duan J; Shang R; Yang W; Wang J; Chen K; Yang F; Jiang T; Lei J
    Int J Surg; 2023 Aug; 109(8):2286-2292. PubMed ID: 37161431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
    Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
    Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer.
    Hu Y; Ren SY; Wang RY; Zeng C; Li JN; Xiao P; Wu F; Yu FL; Liu WL
    Front Oncol; 2021; 11():684070. PubMed ID: 34692476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection 
after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer].
    Liu X; Sun T; Hong T; Yuan Y; Zhang H
    Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):71-77. PubMed ID: 35224959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoimmunotherapy confers survival advantage for patients undergoing sleeve lobectomy.
    Chen T; Wen J; He Y; Zhong Y; Deng J; Chen Q; She Y; Jiang L; Xie D; Zhao D; Chen C
    Eur J Cardiothorac Surg; 2024 Mar; 65(4):. PubMed ID: 38539042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
    Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
    World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
    Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
    Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
    Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
    Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
    Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
    Liu W; Zhang T; Zhang Q; Li L; Xu C
    BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.